Research Paper Volume 11, Issue 13 pp 4338—4353

Targeting HMGB1 by ethyl pyruvate ameliorates systemic lupus erythematosus and reverses the senescent phenotype of bone marrow-mesenchymal stem cells

Figure 2. Normal BM-MSCs were treated with bone marrow supernatant from normal persons or SLE patients, or MSCs were cocultured with SLE bone marrow supernatant treated with anti-HMGB1 mAb. Five groups were analyzed. (A, B) BM-MSCs were fixed and stained with SA-β-gal. (C) MSCs were stained by fluorescein isothiocyanate-conjugated phalloidin. The distribution of F-actin was disordered after treatment with bone marrow supernatant from SLE patients by Immunofluorescence. (D, E) Cell viability was assessed by flow cytometry analysis. (F, G) Normal BM-MSCs were treated with SLE bone marrow supernatant or 100 ng/ml HMGB1, or MSCs were cocultured with SLE bone marrow supernatant treated with anti-HMGB1 mAb. Five groups were analyzed. TLR4, p-IRAK1, p-p65, p53 and p27 expressions were analyzed by western blot. GAPDH was used as the internal control. (Bar represents mean ± SD,*P < 0.05 compared with the normal group, #P < 0.05 compared with the normal group, &P < 0.05 compared with the normal group) (NOR=normal group, SLE=systemic lupus erythematosus patients group).